On yet more worrying news about the omicron variant of the coronavirus, the fortunes of coronavirus stocks were mixed on Tuesday. In contrast the co-developer of Pfizer's jab, BioNTech (NASDAQ: BNTX), was down by almost 3%. It's interesting that the fortunes of partners Pfizer and BioNTech, which together developed the Comirnaty vaccine, were diverging so sharply.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting